SonALAsense
Ben Williams is a co-founder of Stealth Biotech, specializing in first-in-class therapies for adipose tissue with cardiometabolic and aesthetic applications. Holding consulting and advisory roles at Pyro Corp. and serving as an investor and advisory board member for SonALAsense and BioNeex, Ben contributes expertise in startup strategy, product development, and fundraising. Previously, as Chief Business Officer at Keliomics, Ben focused on leveraging human tissues and AI for drug discovery. Ben co-founded 4M Therapeutics Inc. and held leadership positions in ventures such as Diviner, Cellgen Diagnostics, Firecracker, and Firefly Health. Educational achievements include an A.B. in Biology and Health Policy from Harvard University, along with a certificate in Mandarin Chinese from Peking University.
This person is not in any teams
This person is not in any offices
SonALAsense
SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a truedrug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species). The company was founded in 2019 and is based in Berkeley, California.